UNSPSC 51332838: Chlorproethazine hydrochloride

This classification denotes an anticholinergic agent with the molecular formula C19H23ClN2S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 520P4U8V2Z, chemically known as 10h-phenothiazine-3-propanamine, 2-chloro-n,n-diethyl-, monohydrochloride but more generally known as chlorproethazine hydrochloride, which bears US NIH Compound Identifier 65750. European Medicines Agency schedules Chlorproethazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01252MIG.

UNSPSC 51332838 Chlorproethazine hydrochloride is a Commodity code representing pharmaceutical products procured by state and local health agencies, though recent state and local activity under this specific code does not directly align with the code's nominal scope. State and local issuers soliciting pharmaceutical products are pursuing broader generic pharmaceuticals, over-the-counter items, and emergency medical supplies through established cooperative purchasing agreements and competitive bidding processes rather than single-molecule drug procurement. Issuing bodies include state health and human services commissions, county public health departments, and multistate cooperative purchasing alliances. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, and the Texas Health and Human Services Commission represent the largest recent actors, signaling that pharmaceutical procurement at the state and local level increasingly flows through cooperative vehicles and direct-to-manufacturer initiatives rather than traditional single-jurisdiction competitive procurements.

Geographic activity concentrates in Texas, Minnesota, Florida, and Oregon, with Texas and Minnesota driving the most recent volume through statewide initiatives. Representative recent opportunities include MMCAP's generic multi-source pharmaceuticals and OTC products RFP (due March 26, 2026), which establishes multiple contracts across state and local facilities in Minnesota and Oregon with three authorized wholesalers and requires vendors to certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act; Seminole County, Florida's IFB for naloxone and safe drug deactivation systems (due July 26, 2023), calling for 1,900 units of naloxone and 800 deactivation systems annually through quarterly deliveries; and Texas HHS's Request for Information on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program (due April 3, 2026), an early-stage market intelligence effort seeking vendor capabilities for direct state-manufacturer pharmacy contracting. Cooperative purchasing and multistate alignment dominate the procurement landscape, with formal RFP structures and federal compliance requirements (including FEMA and FDA standards) embedded in most solicitations.